Single Subject Neratinib in Bladder Cancer (NRR)

Summary

This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.

Timeline

Start

2013-07

Primary completion

2013-09

Completion

2014-06

Drugs

Indications